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Abstract 
Background: Many patients undergoing surgical procedures experience 
preoperative anxiety. Therefore; develop a drug as a premedication with 
strong anxiolytic effect and minimal psychomotor impairment is desirable.  
Materials and Methods: Under ethics committee approval, eighty patients, 
who met the inclusion criteria, were randomly assigned to two groups to 
receive either oral Valiflore (600 mg, Niak) or placebo as a premedication, 90 
minutes before surgery. A numerical rating scale (NRS) for anxiety and the 
Ramsay sedation scale were measured at baseline, and 15, 30, 60, 90 minutes 
after premedication. Psychomotor function recovery was assessed using the 
Digit Symbol Substitution Test and the Trieger Dot Test on arrival in the 
operating room, 30 and 90 minutes after tracheal extubation. The duration of 
anesthesia, surgery and recovery time were recorded for each patient.  
Results: There were no significant differences in the patients’ demographic 
characteristics, ASA physical status, basal NRS score, the sedation level at 
different time intervals, duration of anesthesia, surgery and recovery time in 
the two groups (p>0.05). The NRS anxiety scores were significantly lower 
in the Valiflore group in comparison with the control group (p<0.001). 
There was no significant difference in psychomotor function test in both 
groups.  
Conclusion: Oral administration of Valiflore as a premedication reduces 
anxiety before surgery without inducing sedation.  
Keywords: Anxiety, Herbal medicine, Premedication, Preoperative anxiety, 
Valiflore 
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Introduction 
Patients undergoing surgical procedures often 
experience high levels of anxiety (1, 2). This anxiety 
may induce adverse effects resulting in unfavorable 
physiological changes, including elevated blood 
cortisol levels and sympathetic hyperactivity leading 
to slower wound healing, decrease immune response 
and increase risk of infection. High anxiety may also 
adversely impact patients’ experience of the surgery 
and intrude treatment process (2-4). 
To reduce patient anxiety, anxiolytic 
premedications are highly recommended (2). 
Benzodiazepines are the most commonly used 
anxiolytic in reducing preoperative anxiety. These 
drugs are frequently accompanied by side effects, 
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such as drowsiness, respiratory suppression and may 
interact with anesthetic agents to prolonged recovery 
and discharge of the patient (3, 5). Therefore, safe 
alternative treatments are considered.  
Phytotherapeutic products have been 
administered increasingly to control anxiety (6, 7). 
Valiflore is an herbal medication containing 
combined extracts of Passiflora incarnata Linneaus 
and Valeriana officinalis. 
Passiflora incarnata L. (Passion Flower) is a 
plant in the family of Passifloraceae that has 
traditionally been used as an anxiolytic and sedative 
worldwide since ancient times (8, 9). Valeriana 
officinalis (Valerian root) is a traditional herbal 
supplement from the Valerianaceae family, which has 
been widely used to reduce anxiety, restlessness, 
somatic arousal, as well as improve sleep disorders 
(10-13). 
The therapeutic efficacy of valerian has been 
confirmed by the European Medicines Evaluation 
Agency in an actual monograph (Committee on 
Herbal Medicinal Products (HMPC/ EMEA) (11).  
To our knowledge, the use of Valiflore on 
anxiety before inducing anesthesia has never been 
evaluated. In this double-blinded, placebo-controlled 
clinical trial, we hypothesized that the use of Valiflore 
as a premedication alleviates preoperative anxiety 
with limited impact on anesthesia and recovery. The 
primary outcome of the present study was to 
investigate the efficacy of preoperative oral 
administration of Valiflore on anxiety levels of 
patients during the preoperative period. The sedative 
effects, psychomotor function, anesthesia duration, 
surgery duration and the recovery period were 
assessed as secondary outcomes. 
Methods 
The study protocol was approved by the 
Tehran University of Medical Sciences Ethics 
Committee and written informed consent was 
obtained from all patients. The trial is registered at the 
Iranian Registry of Clinical Trials (IRCT.ir) with the 
registration number IRCT201404115175N13.  
Eighty patients aged 20–55 years, classified as 
American Society of Anesthesiologists (ASA) 
physical status I and II, who were undergoing elective 
surgical laparoscopic cholecystectomy were enrolled 
in this randomized, double-blinded, placebo-
controlled study. Patients with a history of chronic 
diseases, anxiety and other mental and psychological 
disorders, those consuming any medication 
chronically, including anti-depressant, sedative, 
analgesic and antiepileptic drugs, patients with pre-
operative numerical rating scale for anxiety less than 
one were excluded from the study. 
At the preoperative visit, all patients received 
an explanation of the study plan and the different 
scales used in the study by a trained investigator. An 
anesthesiologist who was not involved in anesthesia 
administration or in patient allocation prepared all 
drugs; thus, patients and investigators were blinded to 
group assignment. Patients were randomly allocated 
into two groups, control (group C, n=40) and 
intervention (group V, n=40) using a computer 
generated randomization list.  
Approximately 2 hours before surgery, patients 
were transferred to a quiet room in the operating suite. 
All patients were assessed by monitoring with an 
electrocardiogram, noninvasive arterial blood 
pressure, and pulse oximetry on arrival to the 
operating room. 
The patients’ level of anxiety was evaluated 
using a Numeric Rating Scale (NRS); a 0–10 scale, 
where 0= no anxiety and 10=the worst possible 
anxiety. Patients’ level of sedation was assessed using 
the Ramsay sedation scale where 1=agitated, anxious 
or restless; 2=cooperative, oriented and tranquil; 
3=responds to commands only, 4=asleep, brisk 
response to light glabellar tap or auditory stimulus; 
5=asleep, sluggish response to light glabellar tap or 
auditory stimulus; 6=asleep, no response (14). 
Instantly prior to receiving the premedication 
or placebo, each patient was assessed for their 
baseline anxiety score using a Numeric Rating Scale 
and their baseline sedation level using the Ramsay 
sedation scale. 
Patients in the control group received a placebo 
tablet and patients in the intervention group received a 
Valiflore tablet orally 90 minutes before surgery. The 
placebo and the active forms of drugs were identical 
in appearance.  
The NRS score and Ramsay sedation score 
were repeated at 15, 30, 60 and 90 (immediately 
before induction of anesthesia) minutes after drug 
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taken. 
Psychomotor function was assessed using 
Trieger Dot Test (TDT) and Digit-Symbol 
Substitution Test (DSST) at preoperative baseline, 30 
and 90 minutes after tracheal extubation. The TDT is 
a variation of the Bender-Gestalt test in which the 
patients were required to arrange a series of dots 
connected in a specific pattern. Points are subtracted 
for missing a dot. TDT deviation represents the 
cumulative distance (in millimeters) between the 
drawn line and missed dots. The DSST is a subtest of 
the Wechsler Adult Intelligence Scale. It is a timed 
paper and pencil test in which patients are asked to 
appropriately match numbers and symbols. The 
number of correct symbols matches during 90 
seconds is the score (6). 
In the operating room, a standard general 
anesthesia method was used in all patients. Anesthesia 
was induced with Alfentanil 15 μg/kg
 
and Propofol 
2.5mg/kg. Cisatracurium 0.2 mg/kg
 
was administrated 
to facilitate orotracheal intubation. Anesthesia was 






Mechanical ventilation was adjusted to 
maintain end-tidal carbon dioxide (ETCO2) pressure 
at 35-40mmHg  level. Patients were actively warmed 
to maintain body core temperature (esophageal 
normothermic). At the end of the surgery, 
neuromuscular block was resolved by the 
administration of neostigmine 2.5mg and atropine 
1mg. The duration of anesthesia, surgery and 
recovery were assessed and recorded for all patients. 
At the post-anesthesia care unit (PACU), 
patients received supplemental oxygen via a nasal 
cannula at 4 liters/minute-1. Postoperative pain was 
treated with 3mg/kg-1 Tramadol during 10 minutes 
infusion. Postoperative nausea and vomiting were 
treated with 4mg Ondansetron intravenously. 
Patients were discharged from the PACU when 
they were awake and oriented, and were able to 
breathe deeply and cough freely, their arterial blood 
pressure was within 20% of preoperative values, their 
body temperature>36°C, and there was no shivering, 
minimal pain, and minimal nausea (15). 
Based on the pilot study of 10 patients, 63% of 
patients experienced moderate to severe anxiety 
(score 4 to 10) before surgery (at 90 minutes). For a 
predicted 50% reduction in the percentages of patients 
experienced anxiety and bringing it to 32 was 
calculated that a sample size of 40 patients in each 
group would be sufficient to detect a three score 
difference in the mean of anxiety score between the 
two groups considering a power of 80%, and a 
significance level of ⍺=0.05.  
Statistical analyses were performed using SPSS 
software (SPSS Inc., Chicago, IL, USA), version 20. 
To compare demographic data, ASA physical status, 
the basal NRS anxiety score, the duration of 
anesthesia, surgery and recovery time between the 
two groups, independent sample t-test was performed. 
The repeated measures analysis of variance 
(ANOVA) was utilized to assess the changes in NRS 
for anxiety between groups and the changes over time 
in each group.  
To compare the sedation scores between 
groups at each measurement time, the Fisher’s exact 
test was used and to compare the sedation scores in 
groups within time, the Friedman test was used. 
Data are presented as mean ± standard 
deviation (SD), median (range), or number 
(incidence) as appropriate. Statistical significance was 
considered significant when P value<0.05. 
Results 
We randomized 80 patients. No patients 
dropped out and all patients were included in the data 
analysis. A flow diagram of conduct of the trial is 
presented in figure 1. 
Patients’ characteristics, ASA physical status, 
the duration of anesthesia, surgery and recovery time 
were similar in the two groups (Table 1). 
The basal NRS anxiety scores were similar in 
the Valiflore group (5.62±0.89) and in the control 
group (5.87±1.06) (p>0.05). A significant difference 
in the mean NRS anxiety scores from the baseline 
was found in the Valiflore group over time (p<0.001) 
(Figure 2).  
Based on Ramsay sedation scores, the sedation 
levels of the patients were similar over time within 
and between groups (Fisher’s exact test, p>0.05; 
Friedman test, p>0.05) (Table 2).  
Psychomotor function scores were similar in 
both groups. The psychomotor function scores were 
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significantly reduced 30 minutes after tracheal 
extubation in both groups; however, within 90 
minutes after extubation they reached baseline values 
(Table 3). 
Discussion 
This study demonstrates that patients who 
received oral premedication with Valiflore 
experienced lower preoperative anxiety compared 
with patients who received placebo. 
 
Figure 1. Flow diagram according to CONSORT statement. 
 
Figure 2. Numeric Rating Scale (NRS) of anxiety at 
different time intervals. 
Table 1: Patient Characteristics. There was no 
significant difference between groups. 
 
 Valiflore 
group      
(n=40) 
Control 
group   
(n=40) 
Age (years) 37.1±8.7 39.5±6.3 
Weight (kg) 64.4±9.4 67.0±10.0 
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Before premedication   
Agitated, anxious or restless 0 0 
Cooperative, oriented and tranquil 40 (100%) 40 (100%) 
Responds to commands only 0 0 
Brisk response to light glabellar tap or auditory stimulus 0 0 
Sluggish response to light glabellar tap or auditory stimulus 0 0 
No response 0 0 
15 min after premedication   
Agitated, anxious or restless 0 0 
Cooperative, oriented and tranquil 40 (100%) 40 (100%) 
Responds to commands only 0 0 
Brisk response to light glabellar tap or auditory stimulus 0 0 
Sluggish response to light glabellar tap or auditory stimulus 0 0 
No response 0 0 
30 min after premedication   
Agitated, anxious or restless 0 0 
Cooperative, oriented and tranquil 40 (100%) 40 (100%) 
Responds to commands only 0 0 
Brisk response to light glabellar tap or auditory stimulus 0 0 
Sluggish response to light glabellar tap or auditory stimulus 0 0 
No response 0 0 
60 min after premedication   
Agitated, anxious or restless 0 1 (2.5%) 
Cooperative, oriented and tranquil 40 (100%) 39 (97.5%) 
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Responds to commands only 0 0 
Brisk response to light glabellar tap or auditory stimulus 0 0 
Sluggish response to light glabellar tap or auditory stimulus 0 0 
No response 0 0 
90 min after premedication   
Agitated, anxious or restless 0 0 
Cooperative, oriented and tranquil 40 (100%) 40 (100%) 
Responds to commands only 0 0 
Brisk response to light glabellar tap or auditory stimulus 0 0 
Sluggish response to light glabellar tap or auditory stimulus 0 0 
No response 0 0 
The onset and the peak effects of Valiflore’s 
anxiolytic activity were observed at 15 and 60 
minutes following oral administration. It was notable 
that the single dose of the Valiflore tablet led to 43% 
decrease in the level of anxiety. 
In both groups, psychomotor impairment 
occurred 30 minutes after surgery; although, they 
returned to the basic levels after 90 minutes.  
Also, the recovery time was similar in both 
groups which present that the administration of 
Valiflore as a premedication does not affect 
psychomotor function or discharge time to home. 
Preoperative Anxiety has been reported in 11–80% of 
adult patients, which can lead to unfavorable health 
outcomes result in longer recovery time and hospital 
stays. Prevention of preoperative anxiety, improves 
surgical outcome and decreases inpatient stay (3, 16).  
Passiflora incarnata and Valerian root are 
popular medicinal plants for the treatment of anxiety 
with a long history of usage in the world (10, 17, 18). 
In Iran, compound drug has been introduced to the 
market with the trade name ‘’Valiflore’’ (Niak R). In 
the present study, the effect of this almost new herbal 
combination on preoperative anxiety was evaluated. 
Passiflora incarnata’s anxiolytic effects have 
been supported in many well-documented studies, 
though; the active phytoconstituents and the exact 
mechanism of action responsible for the therapeutic 
properties have not been identified yet (19). 
The anxiolytic activity of Passiflora incarnata 
has been attributed to mediate via benzodiazepine and 
γ-aminobutyric acid receptors (6, 17). Flavonoids are 
considered for the most probable active ingredient; 
they have anxiolytic properties similar to 
benzodiazepines, and modulate or inhibit GABAA 
and GABAC receptor currents. Chrysin has been 
shown to act as a partial agonist of benzodiazepine 
receptors and GABA was found to be a prominent 
ingredient of Passiflora extract (20, 21). 
The evidences also support the Valeriana 
officinalis’s efficacy and clinical safety in the 
treatment of anxiety with no effect on psychomotor 
performance, alertness or concentration (7, 22). 
Valeriana officinalis was the most reported product 
(19.4%) among herbal products which is used in 
preoperative patients (23). The main active 
constituents of Valeriana officinalis are valerenic acid 
and valepotriates (24). The presence of the anxiolytic 
flavone 6-methylapigenin (MA) in Valeriana 
officinalis also has been reported (13). The exact 
mechanism of action of Valeriana officinalis has 
remained unknown. Neurobiological studies showed 
that valerenic acid interacts within the GABAA-ergic 
system, similarly to a mechanism of action of the 
benzodiazepine drugs, by binding to specific subunits 
of the GABAA receptor complex, result in opening of 
chloride channels and producing neural inhibition. 
Valerenic acid also has been attributed to work via 
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modulation of the serotonergic system, adenosine 
receptors or melatonergic effects (10, 25). 
In a double-blinded, randomized, controlled 
trial (RCT) 60 patients who were scheduled for spinal 
anesthesia were randomly allocated into two groups 
to receive oral Passiflora incarnata aqueous extract 
700 mg 5 ml-1 or placebo. The result of this study 
showed that preoperative oral administration of 
Passiflora incarnata extract suppresses the increase in 
anxiety levels of patients before spinal anesthesia 
without changing in sedation level, psychomotor 
function test results, or hemodynamics (17). 
In another study Passiflora incarnata extract 
was administered as a premedication to control 
presurgical anxiety in patients undergoing elective 
surgery under general anesthesia. A total of 60 
patients was randomized into two groups to receive a 
Passiflora incarnata or a placebo tablet as a 
premedication, 90 minutes before surgery (n=30 for 
each group). The results revealed a significant 
reduction of preoperative anxiety in Passiflora group 
compared with placebo without inducing sedation or 
changing psychomotor function (6). 
Contrary to all these reports, the study by Elsas 
and colleagues; in 2010 showed that Passiflora 
extracts have anxiogenic effects instead of the 
expected anxiolytic effects. The unexpected 
anxiogenic activity of Passiflora extracts may 
attributed to some conditions, such as dosage changes 
in flavonoids, which act as weak agonists to weak 
antagonists at specific GABAA receptor subtypes 
(20). 
There are a few reports of adverse effects 
associated with Passiflora incarnata consumption 
(26), there are no such reports about Valeriana 
officinalis. Nausea, vomiting, prolonged QT, and 
ventricular arrhythmias developed following self-
administration of Passiflora incarnata in a 34 year-
old female patient (27). Hypersensitivity with 
cutaneous vasculitis, urticaria, asthma, and rhinitis 
after ingestion of tablets containing Passiflora extract 
has also been reported (6). Furthermore, Passiflora 
has been attributed to induce uterine contraction so its 
use is contraindicated during pregnancy (6, 17, 27). 
Altered consciousness has been reported after taking 
an herbal compound containing Passiflora incarnata. 
It was recommended not to take Passiflora incarnata 
with CNS depressants or stimulants to minimize 
possible adverse effects on CNS (27) although; these 
side effects are sporadic, and only occurred after 
chronic usage. 
In the study, we used the 600 mg Valiflore 
tablet introduced by Niak pharmaceutical company-
Iran, which may differ from other products in 
constituents or efficacy. It consists of dry extracts 
from Passion flower (30mg) and Valerian (100mg). 











0.8 ± 0.5 0.8 ± 0.3 
TDTmm   
30 min after extubation 
a
 
1.8 ± 1.0 2.0 ± 1.0 
TDTmm 
90 min after extubation 
0.6 ± 0.2 0.7 ± 0.2 
TDTnr 
Preoperative baseline 
0.8 ± 0.3 0.8 ± 0.2 
TDTnr 
30 min after extubation 
a
 
1.9 ± 1.1 1.8 ± 0.8 
TDTnr 
90 min after extubation 
2.8 ± 0.3 0.9 ± 0.5 
DSST 
Preoperative baseline 
25.1 ± 7.2 24.0 ± 6.3 
DSST 
30 min after extubation 
a
 
18.1 ± 7.2 18.2 ± 6.6 
DSST 
90 min after extubation 
21.4 ± 6.2 22.1 ± 6.6 
 
a There was a significant difference 
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Valeriana officinalis extract ratio of 33% and 
Passiflora incarnata extract ratio of 9.9% is prepared. 
The therapeutic dose of Valiflore for anxiety is 
1-2 tablet/s once or twice a day. As Oral 
administration of Valiflore to reduce preoperative 
anxiety has not been evaluated, we used the minimum 
effective dose, a single dose of tablet (600 mg) to 
minimize few possible side effects. At the end of 
surgery, Valiflore presented a better effect than 
placebo. In this study, the patients were not required 
to complete side effect questionnaires, but they were 
asked to verbally report if they experienced any side 
effects both during and at the end of the day and no 
evidence of side effects were reported.  
One limitation of this study was that we 
evaluated the psychological stress with subjective 
assessment tools which are not reliable parameters to 
assess anxiety as they are patient dependent. 
Therefore more physiological parameters such as 
stress biomarkers may have been able to assess subtle 
effects of the medication on the patients’ level of 
anxiety. This would be an interesting consideration 
for future studies. 
Conclusion 
In conclusion, preoperative oral administration 
of Valiflore tablet was effective in reducing anxiety 
without changing in the sedation level or impairing 
psychomotor function compared with placebo. As this 
trial was the first study on the issue, more trials are 
required. 
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